Arbutus Biopharma Corp (ABUS) Financials

ABUS Assets vs Liabilities
DateAssetsLiabilities
Sept. 30, 2026 339.7 million 254.0 million
June 30, 2026 274.0 million 15.3 million
March 31, 2026 277.2 million 17.0 million
Dec. 31, 2025 94.6 million 18.0 million

ABUS Free Cash Flow and Stock based compensation
Graph available only for paid members. Upgrade to see it.
DateFree Cash FlowStock based compensation
Sept. 30, 2026 239.8 million 1.2 million
June 30, 2026 -6.0 million 1.6 million
March 31, 2026 -8.1 million 1.4 million
Dec. 31, 2025 -4.7 million 1.3 million

ABUS Net Income

No data available :(

ABUS Cash and Debt
Graph available only for paid members. Upgrade to see it.
DateCashDebtCapital Lease
Sept. 30, 2026 337.5 million - 328000
June 30, 2026 92.6 million 3.1 million 514000
March 31, 2026 95.2 million 3.3 million 631000
Dec. 31, 2025 91.5 million 3.4 million 199000

ABUS Shares Outstanding
Graph available only for paid members. Upgrade to see it.
DateShares Outstanding
Sept. 30, 2026 199.6 million
June 30, 2026 197.5 million
March 31, 2026 195.2 million
Dec. 31, 2025 191.6 million

ABUS Expenses
Graph available only for paid members. Upgrade to see it.
DateCapexR&DG&AS&M
Sept. 30, 2026 - 2.6 million 8.0 million -
June 30, 2026 6.0 million 2.9 million 3.9 million -
March 31, 2026 8.1 million 4.1 million 5.9 million -
Dec. 31, 2025 4 5.0 million 3.7 million 11000

ABUS Cost of Revenue
Graph available only for paid members. Upgrade to see it.
DateRevenueCost of Revenue
Sept. 30, 2026 299000 -
June 30, 2026 1.0 million -
March 31, 2026 179.1 million 11000
Dec. 31, 2025 1.1 million 11000

ABUS Revenue by Segment
Graph available only for paid members. Upgrade to see it.

ABUS

Price: $4.08

52 week price:
3.50
5.45

Payout Ratio Range:
-71.14%
82.21%

Earnings Per Share: 1.12 USD

P/E Ratio: 3.46

Exchange: NMS

Sector: Healthcare

Industry: Biotechnology

Country: United States

Volume: 545700

Ebitda: -10.9 million

Market Capitalization: 594.8 million

Links: